Treatment and outcomes for patients with bacteremic pneumococcal pneumonia

Medicine

Volumn 87, Issue 3, 2008, Pages 160-166

  Berjohn, Catherine M ^a   Fishman, Neil O ^a   Joffe, Marshall M ^a   Edelstein, Paul H ^a   Metlay, Joshua P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 712 Blockley Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CONFIDENCE INTERVAL; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 44449083712     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e318178923a     Document Type: Article

References (28)

1. AB Biodisk. Etest Technical Manual; 2004.
2. Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, Hoban DJ, Zhanel GG. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother. 2007;51:198-207.
3. Afessa B, Greaves WL, Frederick WR. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis. 1995;21:345-351.
4. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976;43:699-709.
5. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759-776.
6. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489.
7. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother. 2004;54(Suppl 1):i23-i29.
8. Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis. 1985;7:133-142.
9. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect. 2004;48:56-65.
10. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore). 1990;69:307-316.
11. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley C, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
12. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-1457.
13. Hook EWD, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA. 1983;249:1055-1057.
14. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637-644.
15. Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, Melzer E. Pneumococcal bacteremia-no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci. 1987;23:174-180.
16. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-1433.
17. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72.
18. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080-2084.
19. Metlay JP, Fishman NO, Joffe MM, Kallan MJ, Chittams JL, Edelstein PH. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis. 2006;12:1223-1230.
20. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect. 2002;8(Suppl 2):1-11.
21. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med. 1999;107:34S-43S.
22. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, Phan HM, Solomon E. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore). 2000;79:210-221.
23. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: 15th Information Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2005.
24. Pines JM, Hollander JE, Datner EM, Metlay JP. Pay for performance for antibiotic timing in pneumonia: caveat emptor. Jt Comm J Qual Patient Saf. 2006;32:531-535.
25. Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents. 2005;25:282-289.
26. Sorensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31:2097-2100.
27. Werner RM, Bradlow ET. Relationship between Medicare's hospital compare performance measures and mortality rates. JAMA. 2006;296:2694-2702.
28. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.